Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690199 | PMC |
| http://dx.doi.org/10.1093/ibd/izab274 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes of 5-aminosalicylates withdrawal due to non-adherence in ulcerative colitis patients: A step toward evaluating intermittent therapy.
World J Gastroenterol
August 2025
Department of Gastroenterology, Ankara Bilkent City Hospital, Ankara 06800, Türkiye.
Background: 5-aminosalicylates (5-ASA) are the primary treatment for mild to moderate ulcerative colitis (UC). Maintenance therapy with 5-ASA has been shown to reduce both the risk of relapse and colorectal cancer.
Aim: To evaluate the outcomes of 5-ASA withdrawal due to non-adherence in UC patients while in remission on monotherapy.
This study investigated the therapeutic effects and mechanisms of Modified Yiyi Fuzi Baijiang Powder on ulcerative colitis(UC) in rats from the perspective of dampness. SD rats were randomly allocated into six groups(n=10): control, model, mesalazine, and Modified Yiyi Fuzi Baijiang Powder at low(3.96 g·kg~(-1)·d~(-1)), medium(7.
View Article and Find Full Text PDFRepurposing Artrestan (Sacubitril/Valsartan), unveiling its anti-inflammatory and fibrinolytic properties in ulcerative colitis in rats.
Iran J Basic Med Sci
January 2025
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Objectives: Ulcerative colitis (UC) is an inflammatory disorder that is managed with various treatments, which have varying degrees of effectiveness and side effects, highlighting the need for new and more effective alternatives. In this study, we applied Artrestan (Sacubitrol/Valsartan), which has potent anti-inflammatory properties, alone or in combination with mesalazine, in the treatment of UC animal models.
Materials And Methods: Thirty male rats were randomly divided into control, colitis, Artrestan (60 mg/kg/day), mesalazine (100 mg/kg/day), and Artrestan plus mesalazine groups.
Therapeutic potential of alpha-lipoic acid on mitochondrial dynamics, oxidative/nitrosative stress, and histopathological changes in rat ulcerative colitis model.
Inflammopharmacology
September 2025
Department of Basic Pharmaceutical Sciences, Faculty of Pharmacy, Gazi University, Ankara, Türkiye.
Ulcerative colitis is a chronic inflammatory disease affecting the gastrointestinal tract. In addition to treatments aimed at healing inflammation and tissue damage, addressing redox imbalance and mitochondrial dysfunction is crucial. The aim of the present study is to investigate the effects of Alpha-Lipoic Acid (ALA), either alone or in combination with mesalamine, on oxidative/nitrosative stress, mitochondrial dynamics, and histopathological changes in a rat model of ulcerative colitis.
View Article and Find Full Text PDFCannabidiol Enhances the Therapeutic Efficacy of Olsalazine and Cyclosporine in a Murine Model of Colitis.
Int J Mol Sci
August 2025
Department of Medicine and Surgery, University of Parma, 43125 Parma, Italy.
Current therapies for inflammatory bowel disease (IBD), such as olsalazine and cyclosporine, often exhibit limited long-term efficacy and are associated with adverse effects. Cannabidiol (CBD), a non-psychoactive phytocannabinoid, shows promise for its anti-inflammatory properties, though its effectiveness as a monotherapy remains inconclusive. This study investigates the therapeutic potential of combining low-dose CBD (10 mg/kg) with olsalazine (50 mg/kg) or cyclosporine (2.
View Article and Find Full Text PDF